Topics covered: US partnerships, Tax-supporting mechanisms, Specialty pharmaceuticals, Service companies, Promotion of new companies with new technologies, Product development stages, M&A interest, Laterstage clinical development, Lack of IPOs, Introduction of new drugs, Increasingly competitive environment, Emerging biotechnology, Diagnostics, Critical mass, Commercial sales in the US, Attracting capital, Acquisition of technologies and drugs
